Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Epinastine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 13/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 5/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 4/20 | 1.00 |
| ▸ | HTR1A | P08908 | 3/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 3/20 | 1.00 |
| ▸ | DRD1 | P21728 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | SLC22A2 | O15244 | 1/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 1/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 1/20 | 1.00 |
| ▸ | GABRB2 | P47870 | 1/20 | 1.00 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 1.00 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 15/20 | 0.45 |
| ▸ | HTR2C | P28335 | 12/20 | 0.45 |
| ▸ | DRD2 | P14416 | 4/20 | 0.43 |
| ▸ | DRD4 | P21917 | 3/20 | 0.43 |
| ▸ | DRD3 | P35462 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epinastine SCHEMBL29945140 | 1.00 | ADRA1A (1.00) | ADRA1AADRA2AHTR1AOPRM1DRD1 | |
| Epinastine SCHEMBL357588 | 1.00 | ADRA1A (1.00) | ADRA1AADRA2AHTR1AOPRM1DRD1 | |
| Epinastine SCHEMBL122749 | 0.98 | ADRA1A (0.97) | ADRA1AADRA2AHTR1AOPRM1DRD1 | |
| Epinastine SCHEMBL4292213 | 0.98 | ADRA1A (0.97) | ADRA1AADRA2AHTR1AOPRM1DRD1 | |
| Epinastine SCHEMBL3989748 | 0.98 | ADRA1A (0.97) | ADRA1AADRA2AHTR1AOPRM1DRD1 | |
| Epinastine SCHEMBL30678575 | 0.98 | ADRA1A (0.97) | ADRA1AADRA2AHTR1AOPRM1DRD1 | |
| Epinastine SCHEMBL3989750 | 0.98 | ADRA1A (0.97) | ADRA1AADRA2AHTR1AOPRM1DRD1 | |
| Epinastine SCHEMBL122751 | 0.98 | ADRA1A (0.97) | ADRA1AADRA2AHTR1AOPRM1DRD1 | |
| Epinastine SCHEMBL122750 | 0.97 | ADRA1A (0.94) | ADRA1AADRA2AHTR1AOPRM1DRD1 | |
| Epinastine SCHEMBL16093961 | 0.90 | ADRA1A (0.81) | ADRA1AADRA2AHTR1AOPRM1DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 9497 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075669-A | Composition and application thereof in preparation of drugs for preventing and treating lymphoma | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| CN-122020554-A | Automatic identification method and model for tobacco diseases | 昆明学院 | 2026-05-12 | — | — | CN | claimed |
| CN-122023992-A | Tobacco disease diagnosis method and model based on image processing | 昆明学院 | 2026-05-12 | — | — | CN | claimed |
| EP-4724079-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Stealth BioTherapeutics Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-12569451-B2 | Bio-inspired tissue-adhesive hydrogel patch and uses thereof | Cellartgen Inc. (KR) | 2026-03-10 | — | — | US | claimed |
| US-20260048096-A1 | METHODS AND COMPOSITIONS FOR PRESERVING THE RETINAL OUTER NUCLEAR LAYER (ONL), PHOTORECEPTORS, AND RETINAL THICKNESS | STEALTH BIOTHERAPEUTICS INC. (US) | 2026-02-19 | — | — | US | claimed |
| US-12390363-B2 | Ophthalmic drug compositions | OXULAR LIMITED (GB) | 2025-08-19 | — | — | US | claimed |
| EP-4596049-A2 | PEPTIDE FOR USE IN PREVENTING OR TREATING MACULAR DEGENERATION | Stealth BioTherapeutics Inc. (US) | 2025-08-06 | — | — | EP | claimed |
| US-5869479-A | ADMINISTERING HISTAMINE H1 RECEPTOR ANTAGONISTS AND HISTAMINE H3 RECEPTOR ANTAGONISTS; NASAL DECONGESTANT WITHOUT THE NERVOUS SYSTEM OR CARDIOVASCULAR SIDE EFFECTS | SCHERING CORPORATION (US) | 1999-02-09 | — | — | US | claimed |
| CN-1202111-A | Use of epinastine in the treatment of pain | BOEHRINGER INGELHEIM KG (DE) | 1998-12-16 | — | — | CN | claimed |
| CN-1191535-A | Novel pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM KG (DE) | 1998-08-26 | — | — | CN | claimed |
| WO-1998006394-A1 | TREATMENT OF UPPER AIRWAY ALLERGIC RESPONSES WITH A COMBINATION OF HISTAMINE RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 1998-02-19 | — | — | WO | claimed |
| EP-0496306-B1 | Process for the preparation of 3-amino-9,13b-dihydro-1H-dibenz-[c,f]imidazo[1,5-a]azepine hydrochloride | BOEHRINGER INGELHEIM KG (DE) | 1995-09-13 | — | — | EP | claimed |
| US-5312916-A | Process for preparing 3-amino-9,13b-dihydro-1H-dibenz(c,f)imidazo(1,5-a)azepine-hydrochloride | BOEHRINGER INGELHEIM KG (DE) | 1994-05-17 | — | — | US | claimed |
| EP-0345931-B1 | CERTAIN PAF ANTAGONIST/ANTIHISTAMINE COMBINATIONS AND METHODS | SCHERING CORPORATION (US) | 1993-01-20 | — | — | EP | claimed |
| EP-0496306-A1 | Process for the preparation of 3-amino-9,13b-dihydro-1H-dibenz-[c,f]imidazo[1,5-a]azepine hydrochloride | BOEHRINGER INGELHEIM KG (DE) | 1992-07-29 | — | — | EP | claimed |
| EP-0402422-A1 | CERTAIN PAF ANTAGONIST ANTIHISTAMINE COMBINATIONS AND METHODS | SCHERING CORPORATION (US) | 1990-12-19 | — | — | EP | claimed |
| WO-1989010143-A1 | CERTAIN PAF ANTAGONIST ANTIHISTAMINE COMBINATIONS AND METHODS | SCHERING CORPORATION (US) | 1989-11-02 | — | — | WO | claimed |